IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Purchases 20,000 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin purchased 20,000 shares of the company’s stock in a transaction on Tuesday, July 29th. The stock was purchased at an average price of $1.52 per share, with a total value of $30,400.00. Following the completion of the transaction, the insider owned 725,461 shares of the company’s stock, valued at approximately $1,102,700.72. This trade represents a 2.84% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Price Performance

Shares of IRIX stock opened at $0.88 on Thursday. The company has a market capitalization of $15.46 million, a price-to-earnings ratio of -4.40 and a beta of 0.67. IRIDEX Corporation has a one year low of $0.61 and a one year high of $1.65. The company’s fifty day moving average price is $0.73 and its 200-day moving average price is $0.95.

IRIDEX (NASDAQ:IRIX) last released its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The company had revenue of $12.57 million for the quarter, compared to the consensus estimate of $13.59 million. Equities research analysts expect that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, IRIDEX currently has an average rating of “Hold” and an average price target of $3.00.

Institutional Investors Weigh In On IRIDEX

Institutional investors and hedge funds have recently modified their holdings of the stock. Weber Capital Management LLC ADV purchased a new position in shares of IRIDEX in the second quarter worth $206,616. United Capital Financial Advisors LLC purchased a new position in IRIDEX during the second quarter valued at $41,000. Diversify Advisory Services LLC purchased a new position in IRIDEX during the second quarter valued at $30,000. Diversify Wealth Management LLC bought a new stake in IRIDEX in the 1st quarter valued at $35,000. Finally, Bank of New York Mellon Corp bought a new stake in IRIDEX in the 2nd quarter valued at $29,000. Institutional investors own 20.10% of the company’s stock.

Key Headlines Impacting IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.